Single-Arm 36.7% Response Masks Absent OS Proof in Post-Chemo-IO Lung Cancer

Pumitamig Plus Docetaxel Shows Encouraging Phase 2 Results in Advanced NSCLC

BioNTech and Bristol Myers Squibb announced encouraging first data from the global Phase 2 ROSETTA Lung-107 clinical trial, evaluating pumitamig in combination with docetaxel for patients with metastatic non-small cell lung cancer (NSCLC) whose disease progressed after first-line immunotherapy plus chemotherapy. The trial demonstrated significant antitumor activity, with a confirmed objective response rate (cORR) of 36.7% among efficacy-evaluable patients and an early median progression-free survival (PFS) of 6.9 months in the overall treated population. These results, presented at ESMO Congress 2026, are particularly notable given the high unmet need in this patient population, where standard-of-care docetaxel typically yields a median PFS of less than 4 months.

• The ROSETTA Lung-107 trial showed robust efficacy for pumitamig plus docetaxel, achieving a confirmed objective response rate (cORR) of 36.7% and a disease control rate (DCR) of 90.0% in 30 efficacy-evaluable patients. Responses were observed consistently across various PD-L1 expression levels and histologies (squamous and non-squamous NSCLC), indicating broad potential.
• Pumitamig in combination with docetaxel demonstrated an early median progression-free survival (PFS) of 6.9 months in the overall treated population (n=50). This outcome significantly surpasses the historical median PFS of approximately 3.6 to 3.9 months typically seen with standard-of-care docetaxel alone in this heavily pre-treated patient population, addressing a critical unmet medical need.
• The combination therapy exhibited a manageable safety profile consistent with prior datasets, with no new safety signals identified. Treatment-related adverse events (TRAEs) of any grade occurred in 52.0% of patients, with Grade ≥3 TRAEs in 18.0%. This favorable safety profile, alongside the promising efficacy, supports the continued investigation and broad development of pumitamig across multiple lung cancer settings, including seven ongoing Phase 3 trials.

The Unmet Need in Advanced NSCLC After Immunotherapy Progression

Chemotherapy plus immunotherapy is the standard of care for patients with metastatic NSCLC, yet most patients inevitably develop disease progression and mechanisms of resistance to first-line immunotherapy are not clear. Second-line chemotherapies achieve only modest activity following progression under chemo-immunotherapy, highlighting a need for new second-line strategies.

• Metastatic EGFR/anaplastic lymphoma kinase (ALK) wild-type NSCLC with acquired resistance to first-line immunotherapy-based therapy is a targeted population, including progressive disease (PD) after immunotherapy (PD-1/PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy, being evaluated in KeyPemls-004 with pembrolizumab 200 mg D1, plinabulin 30 mg/m D1 and D8, and docetaxel 75 mg/m D1 intravenously for a 21-day cycle.

• Current second-line chemotherapy outcomes remain poor, with median 2L-OS was 8.1 months (95% CI: 6.4-12.7) and median 2L-PFS was 2.9 months (95% CI: 2.4-3.3), and 2L-objective response and 2L-disease control rates were 16.0%, and 42.5%, respectively, across taxane monotherapy, taxane plus anti-angiogenic, platinum-based chemotherapy and other chemotherapy.

• Patients resistant to first line chemo-immunotherapy defined as 1L-PFS < 6 months represent a particularly refractory unmet-need subgroup, with inferior outcomes (2L-OS 5.1 months, 2L-PFS 2.3 months) compared with 1L responders (2L-OS 12.7 months, 2L-PFS 3.2 months).

• Sequential ramucirumab plus docetaxel (RD) after first-line chemoimmunotherapy is an active area of investigation in advanced NSCLC, where performance status, histology (adenocarcinoma), maintenance therapy, and ICI treatment >180 days were significant predictors of better progression-free survival (PFS) and overall survival (OS) after RD administration in 288 patients who received RD as second-line treatment.

ROSETTA Lung-107: Design and Encouraging Pumitamig Phase 2 Results

The LIST study is evaluating the real-world effectiveness, safety and immunotherapy-rechallenge outcomes with nivolumab in previously treated French patients with advanced non-small cell lung cancer. This longitudinal, prospective, observational study enrolled patients with advanced non-small cell lung cancer who received ≥ 1 prior line of treatment that included chemotherapy, with three cohorts based on prior treatment.

Pumitamig's Broad Development Across Lung Cancer and Beyond

The knowledge base does not have sufficient information to answer this question.

Pumitamig-Docetaxel: A New Efficacy Benchmark in Post-Immunotherapy NSCLC

The landscape of advanced non-small cell lung cancer (NSCLC) remains challenging, particularly for patients whose disease has progressed after initial immunotherapy and chemotherapy. This heavily pretreated population faces a significant unmet need, with limited durable treatment options beyond standard docetaxel monotherapy, which typically offers a median progression-free survival (PFS) of less than four months. Against this backdrop, the recent Phase 2 data for pumitamig in combination with docetaxel presents a compelling new development.

The reported confirmed objective response rate of 36.7% and an early median PFS of 6.9 months for the pumitamig combination represent a substantial improvement over historical docetaxel outcomes. This efficacy signal suggests that the combination could establish a new benchmark for treatment in this difficult-to-treat setting, potentially offering patients a much-needed extension of disease control. For BioNTech and Bristol Myers Squibb, these results could pave the way for a strong market entry in a segment where novel therapies are eagerly sought.

However, the path forward is not without its considerations. While promising, these are Phase 2 results, and the full efficacy and safety profile will need to be confirmed in larger, randomized Phase 3 trials. The NSCLC treatment paradigm is also rapidly evolving, with several other innovative agents, such as TROP2-directed antibody-drug conjugates like Dato-DXd and sacituzumab govitecan, as well as KRAS G12C inhibitors, demonstrating superior outcomes compared to docetaxel in similar settings. These emerging therapies will create a competitive environment, necessitating a clear differentiation strategy for pumitamig. Furthermore, docetaxel, while effective, is known for its associated toxicities, including hematological and gastrointestinal adverse events. Careful management of these side effects will be crucial to ensure the combination's overall tolerability and patient quality of life, especially in a population already weakened by prior extensive treatments. The ultimate success of pumitamig will depend on its ability to consistently deliver superior efficacy with a manageable safety profile, securing its place in a complex and competitive treatment sequence.